Propanc Biopharma’s $100M Funding Partnership with Hexstone
Propanc Biopharma secures $100 million in funding with Hexstone, aimed at crypto and cancer therapy innovations.
- Propanc raises $100M with Hexstone for crypto and therapy.
- Funds allocated for crypto treasury and cancer therapy R&D.
- Expectations of institutional interest in ETH, BTC, SOL, INJ.
Propanc Biopharma, in collaboration with Hexstone Capital, has secured up to $100 million to fund both a crypto treasury and its cancer therapy pipeline, announced November 10, 2025.
This funding marks a unique biotech-crypto crossover, impacting potential institutional demand for digital assets like Ethereum and Bitcoin, while quickening Propanc’s oncology developments.
Propanc Biopharma has announced it recently secured up to $100 million in funding. The move aims to build a crypto treasury and accelerate cancer therapy advancements. Important steps are being taken towards a transformative stage in its development.
“This significant capital commitment facilitates a transformative phase for Propanc, both strengthening our financial position and enabling us to accelerate the development of our innovative proenzyme therapy platform.” — James Nathanielsz, CEO, Propanc Biopharma, Inc.
Led by CEO James Nathanielsz, Propanc collaborates with Hexstone Capital. This partnership leverages Hexstone’s expertise in digital asset strategies. The funds target boosting Propanc’s financial strength and expanding its research capabilities.
The direct market impact remains unclear as the funding is structured off-chain. No immediate crypto inflow was reported. Ethereum, Bitcoin, Solana, and Injective could see increased demand if investment plans progress publicly.
Financial implications for Propanc include securing their position in the biotech market. Milestones achieved over 12 months enable access to the full funding. This will likely provide Propanc extensive growth opportunities in research and market position.
The decision to integrate crypto strategies is notable for its rarity in the biotech sector. Propanc’s substantial involvement may set a precedent for similar companies. This move might attract significant institutional interest, altering perspectives on biotech investments.
Potential outcomes include increased regulatory scrutiny as biotech and crypto spaces overlap. Historical trends suggest initial market excitement, but systemic shifts depend on broader institutional engagements. Close monitoring of future on-chain transactions will offer further insights.
